



RNA-Based Vaccines Development

Guest Editor:

Dr. Vrinda Gote

Viral Vaccines R&D, Inventprise
Inc., Redmond, WA, USA

Deadline for manuscript
submissions:

closed (25 August 2024)

Message from the Guest Editor

RNA therapeutics comprise a rapidly expanding category of prophylactic and therapeutic vaccines that will speed up the progression of therapeutics to the clinic. RNA-based vaccines also have the potential to actualize personalized medicine and the ability to make the term “undruggable” obsolete. The recent developments in the upstream generation, downstream purification, and cellular delivery of RNA have enabled the development of RNA-based therapeutics for a variety of vaccines.

The main focus of this Special Issue is to critically analyze the current strategies in the field of RNA-based vaccines against both cancer and infectious disease. We are aiming to shed light on new emerging technologies as well as to illustrate the effect of vaccines. Classes of RNA-based therapeutics include aptamers, antisense oligonucleotides, microRNAs, small interfering RNAs, and messenger RNA. Additionally, articles describing the developments of nanocarriers for RNA-based vaccines are also invited. We also invite papers that describe the advantages and disadvantages of the clinical translation of prophylactic and therapeutic vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)